SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition

European Urology

Volumn 71, Issue 1, 2017, Pages 68-78

  Li, Yinan ^a   Donmez, Nilgun ^a,b   Sahinalp, Cenk ^a,b   Xie, Ning ^a   Wang, Yuwei ^c   Xue, Hui ^c   Mo, Fan ^a   Beltran, Himisha ^d   Gleave, Martin ^a   Wang, Yuzhuo ^a,c   Collins, Colin ^a,b,e   Dong, Xuesen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e Laboratory for Advanced Genome Analysis   (Canada)

Author keywords

Alternative RNA splicing; AR inhibition; Neuroendocrine prostate cancer; SRRM4

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; PROTEIN P53; RE1 SILENCING TRANSCRIPTION FACTOR; RNA; RNA SPLICING FACTOR; SERINE ARGININE REPETITIVE MATRIX 4; TRANSCRIPTION FACTOR; TRANSCRIPTOME; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR; NERVE PROTEIN; SRRM4 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; ARTICLE; BIOINFORMATICS; CASTRATION RESISTANT PROSTATE CANCER; CELL TRANSDIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENETIC REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MALE; MULTICELLULAR SPHEROID; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CELL; RNA SEQUENCE; TRANSCRIPTOMICS; TUMOR MODEL; TUMOR XENOGRAFT; ADENOCARCINOMA; DISEASE EXACERBATION; GENETICS; NEUROSECRETORY CELL; PHYSIOLOGY; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WHOLE EXOME SEQUENCING;

ADENOCARCINOMA; ALTERNATIVE SPLICING; CELL LINE, TUMOR; CELL TRANSDIFFERENTIATION; DISEASE PROGRESSION; HUMANS; MALE; NERVE TISSUE PROTEINS; NEUROENDOCRINE CELLS; NEUROENDOCRINE TUMORS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; WHOLE EXOME SEQUENCING;

EID: 84969921038     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.04.028     Document Type: Article

References (23)

1. [1] Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
2. [2] Hirano, D., Okada, Y., Minei, S., Takimoto, Y., Nemoto, N., Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45 (2004), 586–592 discussion 592.
3. [3] Sasaki, T., Komiya, A., Suzuki, H., et al. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol 48 (2005), 224–230 discussion 229-30.
4. [4] Beltran, H., Rickman, D.S., Park, K., et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1 (2011), 487–495.
5. [5] Terry, S., Beltran, H., The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol, 4, 2014, 60.
6. [6] Lin, D., Wyatt, A.W., Xue, H., et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res 74 (2014), 1272–1283.
7. [7] Lapuk, A.V., Wu, C., Wyatt, A.W., et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 227 (2012), 286–297.
8. [8] Akamatsu, S., Wyatt, A.W., Lin, D., et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep 12 (2015), 922–936.
9. [9] Tan, H.L., Sood, A., Rahimi, H.A., et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res 20 (2014), 890–903.
10. [10] Svensson, C., Ceder, J., Iglesias-Gato, D., et al. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res 42 (2014), 999–1015.
11. [11] Gopalakrishnan, V., REST and the RESTless: in stem cells and beyond. Future Neurol 4 (2009), 317–329.
12. [12] Raj, B., Irimia, M., Braunschweig, U., et al. A global regulatory mechanism for activating an exon network required for neurogenesis. Mol Cell 56 (2014), 90–103.
13. [13] Mosquera, J.M., Beltran, H., Park, K., et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15 (2013), 1–10.
14. [14] Nakano, Y., Jahan, I., Bonde, G., et al. A mutation in the Srrm4 gene causes alternative splicing defects and deafness in the Bronx waltzer mouse. PLoS Genet, 8, 2012, e1002966.
15. [15] Calarco, J.A., Superina, S., O'Hanlon, D., et al. Regulation of vertebrate nervous system alternative splicing and development by an SR-related protein. Cell 138 (2009), 898–910.
16. [16] Bang, Y.J., Pirnia, F., Fang, W.G., et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S A 91 (1994), 5330–5334.
17. [17] Shen, R., Dorai, T., Szaboles, M., Katz, A.E., Olsson, C.A., Buttyan, R., Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol Oncol 3 (1997), 67–75.
18. [18] Zhu, Y., Liu, C., Cui, Y., Nadiminty, N., Lou, W., Gao, A.C., Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). Prostate 74 (2014), 1086–1094.
19. [19] Cortes, M.A., Cariaga-Martinez, A.E., Lobo, M.V., et al. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway. Carcinogenesis 33 (2012), 1169–1177.
20. [20] Sauer, C.G., Roemer, A., Grobholz, R., Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma. Prostate 66 (2006), 227–234.
21. [21] Lotan, T.L., Gupta, N.S., Wang, W., et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 24 (2011), 820–828.
22. [22] Zhang, X., Coleman, I.M., Brown, L.G., et al. SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer. Clin Cancer Res 21 (2015), 4698–4708.
23. [23] Mucci, N.R., Akdas, G., Manely, S., Rubin, M.A., Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 31 (2000), 406–414.